For more than 15 years, we have been immersed in one of the most complex yet fascinating areas of the pharmaceutical industry – data. Our journey started with building and refining databases that help companies navigate APIs, finished dosage forms, excipients, compliance records, and regulatory frameworks. Over time, our work has grown into something larger than a service: it has become a way of connecting people across the industry.
Many of our readers may already know us through our flagship platform, API & FDF Intelligence. Some of you have been our clients for years, while others may be discovering us now. Either way, we see this publication as a natural extension of what we have always done: provide not just information, but perspective. Data by itself is static; it is analysis and interpretation that make it truly valuable.
“Information is the oil of the 21st century, and analytics is the combustion engine.”
— Peter Sondergaard, ex-VP Gartner
This journal was created to share our insights, commentary, and sometimes critical view of the global pharmaceutical landscape. We do not claim to have all the answers, but we do have experience, curiosity, and a strong commitment to transparency. We believe that by putting ideas and analysis into open discussion, we contribute to better decision-making for everyone involved in healthcare and pharma.
We are API DATA, a company registered in Israel, with a long track record of working with manufacturers, regulators, and distributors in many parts of the world. Along the way, we have built countless relationships — sometimes business-oriented, sometimes simply human — with companies and professionals who shape how medicines reach patients. Those encounters fuel our passion for projects like this journal.
“Service to others is the rent you pay for your room here on earth.”
— Muhammad Ali
Finally, it matters to us that our work benefits not only our clients but also the wider community. A part of our income is regularly donated to support volunteer initiatives and charitable causes. It is our way of giving back — because information, when used responsibly, should serve people as much as it serves markets.
Welcome, and thank you for reading.